Hemei Pharmaceutical-B (00054.HK) opens its IPO subscription from October 30 to November 4, planning to globally offer 55.21 million H shares and introducing cornerstone investors including GF Fund Management and China Universal Asset Management.

Zhito Finance APP News, Hemei Pharmaceutical-B (00054.HK) is conducting its IPO from October 30, 2026 to November 4, 2026, intending to globally offer 55.21 million H shares, of which approximately 10% will be offered in the Hong Kong public offering and approximately 90% in the international offering. The offer price is HK$15.5-18.9 per share, with a board lot of 100 H shares. The H shares are expected to commence trading on the Stock Exchange at 9:00 a.m. on Monday, November 9, 2026.